Enterprise and institutional partnerships.

Reserve Meds operates primarily as a patient-facing concierge service, but a growing share of our work is with institutional partners: hospital systems, specialty clinics, payer networks, foundations, and family offices that manage specialty access at scale. This section of the site describes how we engage institutionally, what a partnership looks like in practice, and what an institution should expect from us at each stage of the relationship.

Who this is for

Institutional engagement is typically appropriate for three kinds of partners. The first is hospital systems, particularly multi-hospital systems operating in the countries we serve, where a single coordinated relationship replaces case-by-case intake across multiple sites. The second is specialty clinics, including oncology, rare-disease, and immunology clinics, that manage a recurring volume of cross-border specialty cases and benefit from pre-negotiated documentation, pre-approved receiving SOPs, and a standing case-coordination channel. The third is payer networks and employer health plans, particularly in the Gulf and in India, that offer specialty access as part of a premium benefit and want a named cross-border coordinator under a master agreement. We also engage with family offices, foundations, and patient advocacy organizations where the economics and the case volume justify an institutional relationship rather than a series of individual cases.

What we offer institutional partners

Dedicated case coordination. Institutional partners work with a named Reserve Meds case-coordination lead who owns the relationship end to end, rather than rotating through our general intake queue. The lead is familiar with the institution's receiving SOP, the institution's preferred documentation cadence, and the institution's internal compliance requirements, and the lead is the primary contact for escalations.

Master service agreement. Institutional partners execute a written master services agreement that documents scope, coordination-fee structure, service levels, compliance representations, data handling, adverse-event reporting, dispute resolution, and exit. The agreement is drafted to sit comfortably inside the relevant safe harbors under the US federal Anti-Kickback Statute and under the analogous rules in destination jurisdictions; see the MSA page for structural detail.

Invoice consolidation. Where multiple cases move through a single institutional relationship, we consolidate invoicing into a monthly or quarterly cycle, with per-case detail preserved for the institution's own accounting and compliance records. Payment terms are negotiated case-by-case; the default is prepayment per case, with institutional credit extensions available under the MSA for partners with the appropriate financial posture.

Outcome reporting. Quarterly or annually, depending on the partner's preference, we provide a structured report that summarizes cases coordinated, outcomes recorded, adverse events reported, and service-level metrics against the MSA. The report supports the institution's own board-level reporting and, where applicable, its regulatory filings.

How an institutional relationship typically starts

The first conversation is an exploratory call, without commercial commitment on either side. We listen to the institution's specialty-access needs, describe our capabilities and our limits, and identify whether a deeper engagement is likely to be useful. If both sides decide to move forward, we propose a short pilot: two to five cases under a simplified agreement, at the end of which both sides reassess. The pilot produces a shared record of how the partnership actually works in practice, rather than how each side imagined it would work, and the master service agreement is then drafted on the basis of that shared record.

The pilot approach takes longer than a cold MSA negotiation, and we prefer it for that reason. Specialty-access coordination is a trust-heavy business, and the documents work better when they memorialize a relationship that already has empirical grounding. Partners that require an MSA-first path are accommodated; we simply build in a renegotiation checkpoint at the end of a comparable pilot volume.

What we ask institutional partners to accept

We ask partners to accept three structural constraints. The first is our sourcing posture: every unit moves through DSCSA-serialized US specialty wholesale channels and moves through Altima Care, the US-licensed specialty wholesaler we currently source through, while Reserve Meds advances its own wholesale distributor license and direct manufacturer relationships. We do not substitute to meet a cost target. The second is our clinical and regulatory review posture: every case is reviewed by our AI Clinical Review Agent and AI Regulatory Review Agent, with human sign-off, and we decline cases that fail review. Partners do not pre-approve cases into our pipeline; the review sits at our end. The third is our cash-pay posture: we are not a claims processor, and we do not structure engagements that route payer reimbursement through us. Where a payer partner wants to cover specialty access for enrolled members, the patient or the institution is the commercial counterparty, and the payer's reimbursement of that party is a relationship we sit outside.

Compliance and diligence

For institutional partners that perform a formal supplier qualification on us, we provide the documentation package required. The package typically includes our wholesaler licenses, the DSCSA attestations from our wholesale partners, the pharmacy license, the pharmacist-in-charge identification, our HIPAA and GDPR compliance documentation, our insurance certificates, our anti-money-laundering and sanctions-screening policies, and our adverse-event reporting policy. Where the partner's diligence extends further, we respond with additional documentation on request. We are comfortable being audited; we have nothing we need to hide in our operating posture, and we would rather the documentation discussion happen at the front of the relationship than at the back.

Next step

An institution interested in exploring a partnership can reach out at [email protected] with a short description of the institution, the specialty-access needs at hand, and the geography in play. The initial response is typically within one business day. For the detail on specific institutional segments, see for hospital systems and the master service agreement.

Reviewed 2026-04-22 by Reserve Meds’s AI clinical and regulatory review agents. Human pharmacist-in-charge: Altima Care. Next scheduled review: 2026-10-22.